engleski

Results of the pilot study on molecular characterization of MDR clinical Acinetobacter baumannii isolates from neighbouring countries

Acinetobacter baumannii has emerged as one of the most common nosocomial pathogens worldwide. This organism mostly targets the susceptible immunocompromised patients in ICUs where natural barriers are breached by trauma, surgery or mechanical support ventilation. MDR clinical isolates represent a major problem in the epidemiological and therapeutic sense and challenge for clinicians. Surveillance of carbapenem resistant isolates (which are also multiresistant) of A. baumannii in Croatia is continually monitored since in the last decade the percentage of carbepenem resistant isolates reached 97%. In addition to Croatia, Bosnia and Herzegovina and Serbia also recorded a significant increase in the incidence and prevalence in carbapenem resistant clinically relevant isolates of A. baumannii. The aim of this pilot study was to compare the genotype resemblance and resistance mechanism of 12 isolates of carbapenem resistant A. baumannii collected from three different hospitals in neighbouring countries in region of south-eastern Europe. First results of pilot study were presented on 12th Symposium on the biology of Acinetobacter in Frankfurt during September 2019.

Acinetobacter baumannii, resistance, south-eastern Europe

nije evidentirano